9/21/2021 1:03:37 AM
Regeneron Pharma, Sanofi Present New Dupixent Analyses In Patients With Moderate-to-severe Atopic Dermatitis
9/19/2021 12:02:40 PM
Regeneron Pharma And Sanofi Announce Phase 3 Results For Libtayo Combination Treatment Meets Endpoints
8/30/2021 1:01:42 AM
Regeneron Pharma, Sanofi Announce Phase 3 Results Of Dupixent Meets All Primary And Secondary Endpoints
8/24/2021 7:02:38 AM
Regeneron Announces Encouraging Topline Phase 2 Data Of High-dose Aflibercept In Wet Age-related Macular Degeneration
8/5/2021 6:31:46 AM
Regeneron Q2 Revenues Increase 163% To $5.14 Bln
8/5/2021 6:18:39 AM
Regeneron Pharma And Sanofi: Phase 3 Trial Of Libtayo Combined With Chemotherapy Stopped Early
7/30/2021 2:24:15 PM
Regeneron Pharma Announces FDA Expands Authorized Use Of REGEN-COV
7/29/2021 1:02:58 AM
Regeneron, Sanofi: Phase 3 Trial On Dupixent In Patients With Chronic Spontaneous Urticaria Met Endpoints At 24 Weeks
6/28/2021 1:10:30 AM
Regeneron Pharma And Sanofi: European Medicines Agency To Update Dupixent SmPC Adding Long-term Safety Results